Mapping the genome of chemoresistant ovarian cancer with multi-Omic profiling

This June, the CGC Webinar Series features a talk by Dr. Michelle R. Jones from Cedars-Sinai Medical Center.

In this upcoming webinar, Dr. Jones will present her research on ovarian cancer and how she has used the CGC to map the genome of chemoresistant ovarian cancer with multi-omic profiling. Ovarian cancer is the most lethal gynecologic cancer, with most patients diagnosed at late stage and succumbing to disease due to relapse and the development of chemo-resistance. Paired primary (chemo-naive) and relapse ovarian cancer tumors were profiled for the first time in this study, and revealed large scale conservation of gene regulation and expression throughout disease progression. Insights into the differences in Homologous recombination deficient and proficient tumors implicate differing immune evasion pathways and novel candidates for further study.

More about the speaker

Michelle R. Jones, PhD

Dr. Jones is a research scientist in the Center for Bioinformatics & Functional Genomics at Cedars-Sinai Medical Center. Her lab works on projects that apply genomics methods to improve our understanding of inherited risk for ovarian cancer, and mapping the somatic genome of ovarian cancer to improve our understanding of this lethal gynecological cancer.